• 1
    Arai H. Pharmacotherapy for Alzheimer-type dementia and acetylcholine-Pharmacological effects of donepezil. Jpn J Clin Psychopharmacol 2000; 3: 10011008.
  • 2
    Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1998; 8: 6775.
  • 3
    Burns A, Rossor M, Hecker J et al. The effects of donepezil in Alzheimer's disease—results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237244.
  • 4
    Whitehead A, Perdomo C, Pratt RD et al. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease a meta-analysis of individual patient data from randomized controlled trials. Am J Geriatr Psychiatry 2004; 19: 624633.
  • 5
    Doody RS, Geldmacher DS, Gordon B et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001; 58: 427433.
  • 6
    Black SE, Doody R, Li H et al. Donepezil preserves cognition and global function in patients with severe Alzheimer's disease. Neurology 2007; 69: 459469.
  • 7
    Feldman H, Gauthier S, Hecker J et al. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trail. Int J Geriatr Psychiatry 2005; 20: 559569.
  • 8
    Winblad B, Kilander L, Eriksson S et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Articles 2006; 367: 10571065.
  • 9
    O'Brien J, Ames D, Bums A. Dementia, 2nd edn. London: Arnold, 2000; 332333.
  • 10
    Namba Y, Tomonaga M, Kawasaki H et al. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jacob disease. Brain Res 1991; 541: 163166.
  • 11
    Corder EH, Saunders AM, Strittmatter WJ et al. Gene dose of apolipoprotein E type 4 allele risk of Alzheimer's disease in late onset families. Science 1993; 261: 921923.
  • 12
    Onuma T, Arai H. Apolipoprotein E. Jpn J Geriatr Psychiatry 1998; 11: 13611368.
  • 13
    Choi SH, Kim SY, Na HR et al. Effect of ApoE genotype on response to donepezil in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2008; 25: 445450.
  • 14
    Kumagai R, Matsumiya M, Tada Y et al. Long-term effect of donepezil for Alzheimer's disease: retrospective clinical evaluation of drug efficacy in Japanese patients. Psychogeriatrics 2008; 8: 1923.
  • 15
    Tanaka T, Kazui H, Morihara T et al. Post-marketing survey of donepezil hydrochloride Japanese patients with Alzheimer's disease with behavioral and psychological symptoms of dementia (BPSD). Psychogeriatrics 2008; 8: 114123.